Is This Biotech Trying to Distract Investors?

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.

In today's edition, David and Austin discuss Cell Therapeutics' recent pipeline-bolstering purchase. Normally investors applaud such deals; however, Cell Therapeutics has seen a backlash from the investment community. David and Austin catch viewers up on the controversy and discuss what this deal means for Cell Therapeutics, its shareholders, and its potential competitors.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story